tbuckley/cabot-search huggingface dataset:
AB0228 Evaluation of TP-E Interval and TP-E/QT Ratio as a Predictor of Cardiac Arrhythmias in Autoimmune Rheumatic Disease
Authors: A. Acay, S. Eroglu, O. Akci, G. Ozkececi, G. Acarturk
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Cardiac rhythm disorders in rheumetic diseases are common problems as it is known. <h3>Objectives</h3> In this study it was aimed at investigating whether Tp-e/QT ratio could be an indicator in depicting this risk, in autoimmune rheumatic disease (ARDs) which the ventricular arrythmia frequency increases. <h3>Methods</h3> We enrolled 201 patients with ARDs (48 with ankylosing spondylitis, 21with systemic lupus erythematosus, 64 with rheumatoid arthritis, and 54 healthy controls. Blood samples were taken from all patients for CBC, ESR, CRP, and Anti-SSA/Ro, and Anti-SSB/La. All standart 12-lead ECGs were obtained at rest. The measurements of QT and Tp-e intervals were done. The Tp-e/QT ratio was calculated by using these measurements. <h3>Results</h3> There were no statistically difference between the patients with ARDs and the control group in terms of age, gender, body mass index (BMI), systolic and diastolic blood pressure and heart rate. In patients with ARDs, Tp-e interval and Tp-e/QT ratio were found to be higher when compared to control groups. Moreover, when we analyzed subgroups, Tp-e interval and Tp-e/QT ratio were found to be higher than control group in AS and RA patients (Table). Additionally, there was a correlation between Tp-e interval and Tp-e/QT ratio and inflammatory activity. <h3>Conclusions</h3> Our results demonstrated a higher value of Tp-e interval and Tp-e/QT ratio in patients with ARDs. These electrocardiographic ventricular repolarization indexes were significantly correlated with level of CRP and ESR. Large-scale prospective controlled studies are needed in this area. <h3>References</h3> Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis. 1993;52:174 –6. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res. 2011;63:557–63. Yildirir A, Aksoyek S, Calguneri M, Aytemir K, Kabakci G, Ovunc K, et al. QT dispersion as a predictor of arrhythmic events in patients with ankylosing spondylitis. Rheumatology. 2000;39:875–9. <h3>Disclosure of Interest</h3> None declared
HEALING WITH CARTILAGE
Authors: S Sadiq, S P Rao, S Sathavivalya, K Kangwalklai, I F Enquist
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Surgery of the Stomach and Duodenum
Authors: U G DAILEY
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0505 Long-Term Efficacy and Safety of Mycophenolate Mofetil in Childhood Primary Central Nervous System Vasculitis
Authors: A. Brambilla, A. Cosi, A. Rosati, R. Guerrini, R. Cimaz, G. Simonini
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Childhood primary central nervous system vasculitis (cPANCS) is an inflammatory brain disease targeting either small (angiography-negative) or medium-large (angiography-positive) central nervous system vessels. Vascular inflammation is reversible with proper immunosuppressant treatment, preventing disabling neurologic impairment. <h3>Objectives</h3> To report efficacy and sustained remission in 4 children affected by cPANCS treated with MMF. <h3>Methods</h3> Between December 2011 and August 2014, 4 patients (median age 77 months, range 9-165) were referred to our centre due to stroke symptoms associated to focal areas of acute ischemia at brain neuroimaging. Screening for thromboembolic and metabolic diseases was negative in all patients as well as complete cardiologic evaluation. Antiplatelet and anticoagulant treatments lead to transient clinical and radiological improvement. After a median period of 7 months (range 2-11) they showed clinical and/or radiologic relapse, with documented progression of vascular involvement at magnetic resonance angiography (MRA) or cerebral angiogram. Laboratory work up for infectious diseases, inflammatory and autoimmune conditions excluded secondary causes of central nervous system vasculitis, thus prompting the diagnosis of cPANCS. Methyl-prednisolone (30mg/kg for 3-5 days) was then started, followed by administration of oral Prednisone (1-2 mg/kg/day) and induction therapy with MMF (1000 mg/m<sup>2</sup> divided BID). Brain MRI controls have been performed every 3-6 months according clinical history and neurological evaluation. <h3>Results</h3> Median period of MMF treatment was 18.8 months (range 3-27). Steroid tapering was started after 6 weeks from the beginning and complete discontinuation was achieved within 7-8 months in 3 out of 4 patients. One patient is still on steroid tapering. Periodic clinical examination, blood tests and MRA were performed with evidence of clinical and radiological improvement or, at least, stable findings. In all children, no relapse of cerebral vasculitis occurred during the follow-up period (median 19.8 months, range 5-29). No major side effects and/or drug-related adverse events were documented during the study period of treatment. <h3>Conclusions</h3> Despite the restricted number of enrolled patients, we report efficacy, good tolerance along with persistent improvement and remission in children affected by cPANCS treated with MMF for up to 27 months. <h3>Disclosure of Interest</h3> None declared
Accelerated Drug Approval and Health Inequality
Authors: Alex John London, Jonathan Kimmelman
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Fibrin Monomer Complexes in Pre-Eclampsia
Authors: P S Satoh, W E Fleming, K A Johnston, J M Ozmun
Journal: New England Journal of Medicine (1977)

On the assumption that the number of E-rosettable lymphocytes (active T lymphocytes) is an index of cell-mediated immunity, rosette assays were performed at early cycle and at midcycle for 6 women taking oral contraceptives (OCs) for 1-4 years. OC subjects at midcycle had 21.4% active rosette-forming lymphocytes as compared with 14.1% in controls (p less than .05). The 2 youngest subjects had higher values during the early cycle. These results imply the possibility of hormonal regulation of human T-cell activity.
PTU-203 Hemorpex – effective and safe day case surgical treatment of haemorrhoids in a uk colorectal unit
Authors: P Tozer, J Hollingshead, T Hubbard, R Kanapathippillai, J Smith
Journal: Gut (2015)

<h3>Introduction</h3> The gold standard surgical option for symptomatic haemorrhoids remains haemorrhoidectomy due to its low recurrence rate but alternative options with less postoperative pain (and a slightly higher recurrence rate of around 10–20%) include stapled anopexy and haemorrhoidal artery ligation procedures. Hemorpex is a newer and cheaper technique in which arterial ligation is performed without the need for an expensive doppler probe. Previous studies have reported success rates of 70–90% with little postoperative pain. We present our first 3 years’ experience with this technique. <h3>Method</h3> Retrospective data were collected from hospital records on consecutive patients undergoing the Hemorpex procedure in a single centre over a 3 year period from June 2009 to June 2012. Patients under general or regional anaesthesia in the prone position had 6 spiral sutures placed in the 1, 3, 5, 7, 9 and 11 o’clock positions using the Hemorpex operating proctoscope. Skin tag excision was performed concurrently where appropriate. Demographic and outcome data were collected including admission, readmission, recurrence rates and postoperative complications. <h3>Results</h3> Some 248 patients underwent Hemorpex, as a day case in 94% of cases. The mean operating time was 27 min (SD 9.8 min). General anaesthesia (68%), spinal (30%) or caudal epidural (1%) were used. Early postoperative complications included acute urinary retention (4%), post-operative pain (3%) and minor post-operative bleeding (3%) none of whom required overnight admission. Nine percent required readmission, mostly for pain or bleeding. Fifteen percent presented with recurrence. Twelve percent required reintervention of whom half underwent redo Hemorpex or haemorrhoidectomy and a third required either office based treatment or skin tag excision. <h3>Conclusion</h3> Hemorpex is a successful day case technique for the surgical management of haemorrhoids with low morbidity and recurrence rate equivalent to similar procedures but without equivalent cost. <h3>Disclosure of interest</h3> None Declared.
GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure
Authors: Inga Hofmann, Daniel Kierstead, Jennie Krasker, Dean Campagna, Klaus Schmitz-Abe, Kyriacos Markianos, Michelle A Lee, Colin A. Sieff, Suneet Agarwal, Jennifer J Clark, Michael Jeng, Mignon L. Loh, Evan Shereck, David A. Williams, Mark D Fleming
Journal: Blood (2013)
Hyperlipemia of Antiserum Nephrosis: III. Plasma Lipoproteins
Authors: H S SODHI, N KALANT
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0138 Comparison of Golimumab Levels Detected by Two Different Enzyme-Linked Immunosorbent Assays: Promonitor VS Sanquin
Authors: T. Jurado, C. Plasencia, S. Martin, R. Navarro, G. Bonilla, A. Villalba, S. Ramiro, A. Jochems, A. Balsa, D. Pascual-Salcedo
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Golimumab (GLM) is a fully human monoclonal antibody to TNFa and it is an inhibitor that binds to both transmembrane and soluble bioactive human TNFa and blocks their action. This TNF-inhibitor is used in the treatment of the rheumatoid arthritis (RA), ankylosing spondilitis (AS) and psoriatic arthritis (PsA). Recently it has been reported that there exists a significant relationship between GLM levels circulating in serum and the patients9 response. Therapeutic drug monitoring (TDM) with serum level measurement can be a useful tool to optimization of the anti-TNF treatment, but the lack of standardization can hinder the comparison. <h3>Objectives</h3> To determine the correlation and agreement between two different Enzyme-Linked Immunosorbent Assay (ELISA) assays for measuring golimumab. <h3>Methods</h3> A total of 121 sera from a cohort of 44 patients under golimumab treatment with different rheumatic diseases (RA, AS and PsA) were analyzed. The golimumab trough levels were analyzed at the beginning of the treatment and every 6 months to 2 years of treatment. The serum levels were analyzed in blind manner by the Immunology Unit from the La Paz University Hospital (Madrid, Spain) using the commercial Kit Promonitor®-GLM (Progenika, Biopharma SA, Derio, Vizcaya) and by Sanquin Diagnostic Services (Amsterdam, The Netherlands) using an own developed ELISA. The statistical analysis to quantify the correlation and the agreement between GLM levels were made with SPSS version 20 (IBM, New York, NY, USA) and with GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA). <h3>Results</h3> The correlation between GLM levels of the different two assays was r Pearson of 0.963 (p&lt;0.001). Qualitatively, GLM levels were detected in only one serum with the Sanquin assay whereas in the Promonitor®-GLM this serum was negative. The agreement between GLM levels of the two different assays was analyzed using an intraclass correlation coefficient (ICC). We obtained an ICC =0.96 (95% CI 0.944-0.972; p&lt;0.001). These data were represented by a Bland-Altman plot (fig.1) where we obtained an average of differences of 25.56 with a 95% limit of agreement (-570.2 - 621.3), indicating that the two assay methods produce similar results. <h3>Conclusions</h3> There is an excellent correlation and agreement between GLM levels obtained with the commercial Kit Promonitor®-GLM and the levels obtained in the Sanquin laboratory, both of them with ELISA technology. These results may help us to standardize the GLM levels and the comparisons between different data reported with either of these two assays. <h3>Disclosure of Interest</h3> None declared
Serological surveillance of rubella in Europe: European Sero-Epidemiology Network (ESEN2)
Authors: A Nardone, E Miller
Journal: Eurosurveillance (2004)

Serological surveillance is an important resource to evaluate vaccine programmes, especially for diseases such as rubella, where a sub-optimal programme can lead to an increase in morbidity. A coordinated vaccine policy in Europe is needed and the aim of the European Sero-Epidemiology Network (ESEN2) is to standardise serological surveillance in 22 countries for eight diseases, including rubella.
THE "ART" AND "SCIENCE" OF MEDICINE
Authors: J Parving, A Parving
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of animals in medical education
Authors: D E Kelly
Journal: JAMA (1991)

<h3>To the Editor.</h3> — I am writing in response to the Council on Scientific Affairs' "Use of Animals in Medical Education" article.<sup>1</sup>The authors would have us believe that the only people opposed to the use of animals in medical education are those who break into laboratories, deface them with graffiti, and deal out death threats. Not so: thousands of physicians, many of them AMA members, are opposed to such use. I recall from my medical school days watching a guinea pig, strategically placed on the professor's desk, die from anaphylactic shock when challenged with an allergen. It is hard to imagine that I could not have learned this equally well by reading about it or watching a computer simulation. I tried to learn about the use of epinephrine on cat muscle while repressing my horror at watching a live cat used in the demonstration. I have often thought
Heme Oxygenase-1 and Carbon Monoxide in the Heart
Authors: Leo E. Otterbein, Roberta Foresti, Roberto Motterlini
Journal: Circulation Research (2016)

Understanding the processes governing the ability of the heart to repair and regenerate after injury is crucial for developing translational medical solutions. New avenues of exploration include cardiac cell therapy and cellular reprogramming targeting cell death and regeneration. An attractive possibility is the exploitation of cytoprotective genes that exist solely for self-preservation processes and serve to promote and support cell survival. Although the antioxidant and heat-shock proteins are included in this category, one enzyme that has received a great deal of attention as a master protective sentinel is heme oxygenase-1 (HO-1), the rate-limiting step in the catabolism of heme into the bioactive signaling molecules carbon monoxide, biliverdin, and iron. The remarkable cardioprotective effects ascribed to heme oxygenase-1 are best evidenced by its ability to regulate inflammatory processes, cellular signaling, and mitochondrial function ultimately mitigating myocardial tissue injury and the progression of vascular-proliferative disease. We discuss here new insights into the role of heme oxygenase-1 and heme on cardiovascular health, and importantly, how they might be leveraged to promote heart repair after injury.
Adherence reporting in phase III trials of approved oral anticancer agents: A systematic review.
Authors: R Donald Harvey, Trevor McKibbin, Madhusmita Behera, Suresh S Ramalingam
Journal: Journal of Clinical Oncology (2013)

e20596 Background: With the increasing number of orally administered anticancer agents, evaluation of treatment adherence is critical to assess efficacy and adverse events. When patients enrolled in registration clinical trials do not adhere to the investigational agent(s), conclusions made regarding efficacy and safety may be inaccurate and translate poorly to broader use. We performed a systematic review of adherence reporting in phase III trials of oral anticancer agents. Methods: We selected all oral anticancer agents approved by the FDA between 1996 and 2012. A PubMed search for generic name, with limits to "title" and "clinical trials", was performed. Publications from phase III trials were identified from the results. Medication adherence data were abstracted searching for the roots “compli” and “adher” and were categorized as follows: 1) mentioned or not, 2) methods described or not and 3) results reported or not. Results: Overall, publications or reports with 24 agents were identified. The search strategy yielded 5383 articles, of which 504 reporting on phase III trials were included for analysis. Of these, 106 (21%) mentioned either adherence or compliance to medications. Only 33 (7%) publications described methods of measuring adherence (e.g., diaries, interviews, pill counts), while 37 (7%) reported medication adherence results. Trials specifically identifying quantitative or qualitative rates of adherence in phase III trials involved abiraterone, anastrozole, capecitabine, dasatinib, exemestane, imatinib, lapatinib, letrozole, tamoxifen, thalidomide, topotecan, and toremifene (50% of agents). Within the 37 trials reporting adherence, 12 were qualitative (e.g., excellent, poor), 23 were quantitative, and 2 used pharmacokinetically-defined adherence measures. Conclusions: Medication adherence is infrequently reported in phase III trials of oral anti-cancer agents, leading to a knowledge gap in translation to clinical use. Our study underscores the need for standard metrics on measuring and reporting adherence to oral anticancer agents.
Sentinel surveillance of sexually transmitted diseases in Italy
Authors: M Giuliani, B Suligoi, Collective the STD Surveillance Working Group
Journal: Eurosurveillance (1998)

Statutory notifications suggest that the incidence of gonorrhoea and syphilis have fallen in the past 30 years in Italy, as in other developed countries. Nevertheless, during the 1980s, the annual notification rates in Italy were from 15 to 50 times lower